Business Wire

Knopp Biosciences Receives Key Patent Directed to Treatment for Hypereosinophilic Syndromes, Asthma, and Other Eosinophilic Diseases

Del

Knopp Biosciences LLC today announced it has received United States Patent No. 9,468,630 entitled “Compositions and Methods for Treating Conditions Related to Increased Eosinophils.”

The patent relates to the company’s clinical-stage small molecule dexpramipexole, which Knopp expects to advance into pivotal trials in hypereosinophilic syndromes (HES) and Phase 2 trials in eosinophilic asthma in 2017. U.S. Patent No. 9,468,630 specifically claims methods of treating HES and asthma by administering therapeutically effective amounts of dexpramipexole. Issued claims are also directed to methods of treating nasal polyposis, eosinophilic gastroenteritis, eosinophilic esophagitis, and atopic dermatitis, by administering therapeutically effective amounts of dexpramipexole. Eosinophils are white blood cells associated with inflammation.

“Issuance of this patent further strengthens our efforts to advance dexpramipexole as a small molecule treatment for HES, eosinophilic asthma, and other eosinophil-associated diseases,” said Michael Bozik, M.D., President and CEO of Knopp. “Recent drug approvals have confirmed the benefit of lowering eosinophil levels to reduce the risk of asthma exacerbations through the infusion or injection of monoclonal antibodies. We are developing dexpramipexole to provide the benefits of an oral, small molecule alternative for lowering eosinophils in HES and asthma.”

Two ongoing, proof-of-concept Phase 2 trials are currently characterizing the eosinophil-lowering effects of dexpramipexole in eosinophil-associated diseases. A 20-subject, multi-center, pilot study of dexpramipexole is nearing completion in subjects with chronic rhinosinusitis and nasal polyps with eosinophilia. A separate pilot study under the sponsorship of the National Institutes of Health is evaluating dexpramipexole as a steroid-sparing agent in hypereosinophilic syndromes (HES).

The targeted eosinophil-lowering effects of dexpramipexole were previously observed at doses of dexpramipexole well tolerated in earlier clinical studies of more than 1,000 subjects with amyotrophic lateral sclerosis (ALS).

Prosecution of the patent was led by Raymond A. Miller and N. Nicole Stakleff of the Intellectual Property Department of Pepper Hamilton LLP.

ABOUT KNOPP BIOSCIENCES LLC

Knopp Biosciences, based in Pittsburgh, PA, USA, is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need in clearly defined patient populations. Our clinical-stage small molecule, dexpramipexole, is entering Phase 2 clinical studies in eosinophilic asthma. Our preclinical platform is directed to small molecule treatments for neonatal epileptic encephalopathy, a devastating brain disorder of infants caused by a rare mutation in the KCNQ2 gene. For more information, see www.knoppbio.com.

ABOUT PEPPER HAMILTON LLP

Pepper Hamilton LLP is a multi-practice law firm with more than 450 lawyers nationally. The firm provides corporate, litigation, and regulatory legal services to leading businesses, governmental entities, nonprofit organizations, and individuals throughout the nation and the world. The firm was founded in 1890. For more information, see www.pepperlaw.com.

Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.

This release contains “forward-looking statements,” including statements that may relate to Knopp’s plans regarding regulatory filings and clinical development programs for dexpramipexole and other compounds and future financing and strategic alternatives. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties, and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of potential alternative therapies or treatments, the availability of patent protection for the discoveries and the availability of strategic alliances, as well as additional factors that may cause Knopp’s actual results to differ from our expectations. There can be no assurance that dexpramipexole or any other compound will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market the products. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact information

Knopp Biosciences LLC
Tom Petzinger
+1-412-488-1776
tom@knoppbio.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

TRIGO Deepens its Expansion into the USA by Acquiring Lumbee Enterprises23.7.2018 13:00Pressemelding

TRIGO has acquired 100% of the capital of Lumbee Enterprises based in Greer, SC. This acquisition allows TRIGO to deepen its expansion into the USA within the automotive industry. Lumbee began providing supply chain and logistics services over 25 years ago and it’s TRIGO’s intent to leverage Lumbee’s proven expertise to further expand its business. Lumbee is best known for its expertise in Quality Manufacturing, Sorting, Inspection and Sub-Assembly Operations, specializing in providing best-in-class inspection and rework services to keep OEM assembly lines running seamlessly and without interruption. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180723005040/en/ Co-founded by Colby Griffin in 2001, LUMBEE Enterprises of South Carolina has focused on providing quality management services to shorten supply chain interruptions through the innovative use of technology and processes. “This acquisition is a great opportunity for

STATS Taps Dr. Helen Sun, Former CTO of JPMorgan Chase Commercial Banking Division, to Lead STATS’ Technology Operations23.7.2018 11:00Pressemelding

Today, STATS, the worldwide leader in sports data and intelligence, expanded its executive roster with the introduction of Dr. Helen Sun as Chief Technology Officer. Sun will oversee STATS’ product, engineering, artificial intelligence and data production teams in developing the next generation of products and services that will revolutionize the performance and experience of sports. Sun joins STATS from JPMorgan Chase, most recently serving as Chief Technology Officer of the Commercial Banking division. For over 22 years, Sun has a proven record as a technology strategist and thought leader in previous roles as Vice President of Cloud Computing, Information Management, and Architecture at Motorola Solutions; Senior Director of Global Enterprise Architecture at Salesforce; and Director of Enterprise Architecture at Oracle. “Helen is a leader in transforming businesses through innovative solutions and she will be a driving force in building upon our reputation as the leading sports tech

IBC2018 Enhances Conference Programme with Keynote Sessions from Amazon, Viacom and Wonderhood Studios23.7.2018 10:57Pressemelding

IBC2018, the world’s most influential media, entertainment and technology show, today announces three new Keynote speakers from globally renowned media and entertainment powerhouses. The addition of executives from Amazon, Viacom and Wonderhood Studios adds to the big-name line up of thought provoking and informative sessions and speakers already announced by IBC. Taking to the stage on the first day of the conference, Thursday 13 September, to deliver the Trailblazer Keynote session entitled ‘Give Your Vision a Voice’ is Max Amordeluso, EU Lead Evangelist Amazon Alexa, Amazon. As voice assistants such as Amazon Alexa are transforming the way audiences discover content and control devices, Amordeluso’s must-attend presentation will explore a variety of avenues, including: how to build a voice strategy with Alexa; why voice experiences are now a crucial part of any multi-platform content business; how to implement an engaging voice strategy for content products and generate new revenues

SIGOS: Digital Experience - 120 mobile network operators from 60 countries meet in Nuremberg23.7.2018 10:06Pressemelding

For more than 10 years, SIGOS has been inviting mobile network operators from all over the world to the annual telecommunications conference. After venues such as Düsseldorf, Berlin, Munich, Beijing, Kuala Lumpur, etc., this year's multi-day conference took place at the Nuremberg convention centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180723005282/en/ SIGOS conference panel discussion - photo: www.uwe-niklas.com Over 120 network operators and telecommunications companies from over 60 countries worldwide came together to talk about the latest innovations in areas such as network quality, performance, 5G, IoT, roaming, and telecommunications fraud detection solutions. Dr. Ulrich Maly, Lord Mayor of the City of Nuremberg, welcomed the international audience in his opening speech and explained:"...when we talk about mobile communication, then we talk about people and their needs that are and should be the focus of atte

AURAK Enters into a Memorandum of Understanding with Al-Farabi Kazakh National University22.7.2018 09:52Pressemelding

The American University of Ras Al Khaimah (AURAK) President, Professor Hassan Hamdan Al Alkim, and the Al-Farabi Kazakh National University (KazNU) Rector, Professor Galimkair Mutanov, of the Republic of Kazakhstan, signed a Memorandum of Understanding (MoU), agreeing to exchange students, faculty, and research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180722005025/en/ The Al-Farabi Kazakh National University (KazNU) Rector, Professor Galimkair Mutanov, of the Republic of Kazakhstan and the American University of Ras Al Khaimah (AURAK) President, Professor Hassan Hamdan Al Alkim, exchange a gift to commemorate their universities uniting in an MoU agreement. (Photo: AETOSWire) In the spirit of fostering a close international relationship between the Republic of Kazakhstan and the United Arab Emirates, developing bilateral relations in educational and scientific fields, and wishing to make their own contributions to the

Philip Morris International Announces Non-Executive Board Chairman Louis Camilleri to Assume CEO Role at Ferrari S.p.A.21.7.2018 18:19Pressemelding

The board of directors of Philip Morris International (NYSE:PM) has its board member, Sergio Marchionne, and his family in our thoughts and prayers during this challenging time. We congratulate our board chairman, Louis Camilleri, as he assumes the role of CEO of Ferrari S.p.A. The long term relationship between our two companies is deep and meaningful and we look forward to continued business collaboration. Mr. Camilleri will continue to serve as non-executive chairman of the PMI board. Philip Morris International: Who We Are We are a leading international tobacco company engaged in the manufacture and sale of cigarettes and other nicotine-containing products in markets outside the United States of America. We’re building our future on smoke-free products. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, we aim to ensure that our smoke-free products meet adult consumer preferences and rigorous regulatory requirem